UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

Proteasome inhibitors for the treatment of multiple myeloma

Expert opinion on pharmacotherapy, 2018-03, Vol.19 (4), p.375-386

2018

Link zum Volltext

Verfügbarkeit prüfen

Solitary Plasmacytoma

Mediterranean journal of hematology and infectious diseases, 2017-08, Vol.9 (1), p.e2017052-e2017052

2017

Link zum Volltext

Verfügbarkeit prüfen

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience

Annals of hematology, 2020-10, Vol.99 (10), p.2405-2416

2020

Link zum Volltext

Verfügbarkeit prüfen

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

Therapeutic Advances in Hematology, 2019, Vol.10, p.2040620719826444-2040620719826444

2019

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Infectious prophylaxis in hematological malignancies

Frontiers in oncology, 2023-05, Vol.13, p.1163175

2023

Link zum Volltext

Verfügbarkeit prüfen

Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab

Annals of hematology, 2021-08, Vol.100 (8), p.2117-2119

2021

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination

Frontiers in oncology, 2023-06, Vol.13, p.1212638

2023

Link zum Volltext

Verfügbarkeit prüfen

Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs

American journal of hematology, 2020-10, Vol.95 (10), p.E260-E263

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Annals of hematology, 2022-06, Vol.101 (6), p.1275-1282

2022

Link zum Volltext

Verfügbarkeit prüfen

Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report

Frontiers in oncology, 2024-01, Vol.13, p.1338417

2024

Link zum Volltext

Verfügbarkeit prüfen

Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib

Annals of hematology, 2021-08, Vol.100 (8), p.2005-2014

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients

Annals of hematology, 2021-05, Vol.100 (5), p.1213-1219

2021

Link zum Volltext

Verfügbarkeit prüfen

Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients

Annals of hematology, 2020-12, Vol.99 (12), p.2773-2777

2020

Link zum Volltext

Verfügbarkeit prüfen

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

Annals of hematology, 2019-08, Vol.98 (8), p.1919-1925

2019

Link zum Volltext

Verfügbarkeit prüfen

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Blood cancer journal (New York), 2022-09, Vol.12 (9), p.132-132, Article 132

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia

Journal of clinical medicine, 2024-01, Vol.13 (1), p.273

2024

Link zum Volltext

Verfügbarkeit prüfen

Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors

Annals of hematology, 2020-07, Vol.99 (7), p.1525-1530

2020

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation

Journal of clinical medicine, 2022-09, Vol.11 (19), p.5594

2022

Link zum Volltext

Verfügbarkeit prüfen

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?

Journal of clinical medicine, 2022-05, Vol.11 (9), p.2596

2022

Link zum Volltext

Verfügbarkeit prüfen

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Blood cancer journal (New York), 2020-06, Vol.10 (6), p.66-66, Article 66

2020

Link zum Volltext

Verfügbarkeit prüfen

Asciminib: an investigational agent for the treatment of chronic myeloid leukemia

Expert opinion on investigational drugs, 2021-08, Vol.30 (8), p.803-811

2021

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic strategies in low and high-risk MDS: What does the future have to offer?

Blood reviews, 2021-01, Vol.45, p.100689-100689, Article 100689

2021

Link zum Volltext

Verfügbarkeit prüfen

Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice

Leukemia & lymphoma, 2023-12, Vol.64 (14), p.2324-2326

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(79)
Berichte
(5)

Sprache

Englisch
(84)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(62)
Science & Technology
(62)
Hematology
(47)
Humans
(39)
Oncology
(35)
Chronic Myeloid Leukemia
(31)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(23)
Leukemia
(22)
Male
(18)
Aged
(16)
Female
(16)
Medicine
(15)
Medicine & Public Health
(15)
Middle Aged
(15)
Retrospective Studies
(15)
Protein Kinase Inhibitors - Therapeutic Use
(14)
Adult
(13)
Treatment Outcome
(13)
Aged, 80 And Over
(12)
Original Article
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Proteasome inhibitors for the treatment of multiple myeloma

Solitary Plasmacytoma

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

Case Report: Infectious prophylaxis in hematological malignancies

Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination

Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs

Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report

Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients

Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia

Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation

PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT‐FREE REMISSION (TFR) IN CHRONIC PHASE‐CHRONIC MYELOID LEUKEMIA (CP‐CML) PATIENTS TREATED WITH TKI

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Asciminib: an investigational agent for the treatment of chronic myeloid leukemia

Therapeutic strategies in low and high-risk MDS: What does the future have to offer?

Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice

Suchergebnisse filtern